These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37013299)
21. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Shih HI; Wu CJ; Tu YF; Chi CY Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623 [TBL] [Abstract][Full Text] [Related]
22. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Vaccines: Status Report. Amanat F; Krammer F Immunity; 2020 Apr; 52(4):583-589. PubMed ID: 32259480 [TBL] [Abstract][Full Text] [Related]
24. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
25. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19). Bennet BM; Wolf J; Laureano R; Sellers RS Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660 [TBL] [Abstract][Full Text] [Related]
26. Heterologous immunity induced by 1 Patel RS; Agrawal B Front Immunol; 2022; 13():952229. PubMed ID: 36045689 [TBL] [Abstract][Full Text] [Related]
27. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
28. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
29. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Chavda VP; Bezbaruah R; Athalye M; Parikh PK; Chhipa AS; Patel S; Apostolopoulos V Viruses; 2022 Apr; 14(4):. PubMed ID: 35458489 [TBL] [Abstract][Full Text] [Related]
30. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. Chauhan N; Soni S; Gupta A; Aslam M; Jain U J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225 [TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
34. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298 [TBL] [Abstract][Full Text] [Related]
36. Coronavirus Vaccine: Light at the End of the Tunnel. Ella KM; Mohan VK Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382 [TBL] [Abstract][Full Text] [Related]
37. Super-rapid race for saving lives by developing COVID-19 vaccines. Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582 [TBL] [Abstract][Full Text] [Related]
38. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. McAteer J; Yildirim I; Chahroudi A Clin Infect Dis; 2020 Jul; 71(15):703-705. PubMed ID: 32282038 [TBL] [Abstract][Full Text] [Related]
39. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B Cells; 2022 Mar; 11(7):. PubMed ID: 35406746 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]